CODIT™: Our investigational approach to treating food allergies
Developing a standardized approach to oral immunotherapy to treat food allergies, starting with peanut allergy.
Building on this legacy of OIT research, Aimmune’s investigational CODIT approach (Characterized Oral Desensitization Immunotherapy) is now being developed as a standardized approach to treat food allergies, starting with peanut allergy. CODIT is being developed with three key elements:
- A standardized OIT protocol with precise oral dosing
- Characterized pharmaceutical products
- Training and education
We plan to use our investigational CODIT approach with additional development programs for other food allergies beyond peanut.
Using our investigational CODIT approach and associated pharmaceutical products, we seek to help food-allergic individuals reduce the risk of life-threatening reactions due to accidental exposure to food allergens.
The CODIT Approach
Our investigational CODIT approach is based on precise, incremental dosing of a characterized food allergen to achieve gradual desensitization, followed by a daily maintenance dose. The aim of CODIT is to provide an approach for predictable, reliable implementation of OIT that meets the requirements for regulatory approval.
With our investigational CODIT approach, initial administration of a particular dose of food allergen would be done in an allergist’s office, and subsequent administrations would be done at home until the next up-dosing in the allergist’s office. Once desensitized, patients would take a daily maintenance dose to maintain desensitization, and would continue to avoid exposure to their food allergens and carry epinephrine auto-injectors.